The Rising Tide Foundation for Clinical Cancer Research is issuing a request for proposals focused on therapy de-escalation in pediatric neuro-oncology.
The Rising Tide Foundation for Clinical Cancer Research is excited to announce the opportunity for funding interventional clinical trials on therapy de-escalation in pediatric neuro-oncology
with the aim to reduce both short- and long-term treatment-associated toxicity. There is a critical unmet need to reduce the burden of toxicity caused by current practice use of
therapeutic agents while maintaining efficacy. This request for proposals (RFP) welcome trials focused on therapy toxicity de-escalation in all types of pediatric central nervous system
tumors, such as changing the administration schedule, de-escalating surgery, or radiotherapy, decreasing the dose or changing the combination therapy. Some examples of de-escalation are
targeted therapy (such as MEK inhibitor) in low-grade gliomas, vincristine, steroid use for side effect management.
We encourage clinical trials that include measurements of biomarkers / biological features to correlate de-escalation while maintaining efficacy, as well as those that measure special adverse
effects to determine potential improvement in toxicity, such as patient-reported or neurologic outcomes. Phase I, II or multicenter phase III clinical trials are strongly recommended.
The total budget for this RFP is USD 2 million. The amount allocated per grant will depend on the number of applications selected for funding.
Application Deadline:11 December 2023, 23:59 CET
Please find the full information here
Regards,
Paola Atzei, Ph
Senior Scientific Program Manager
Herrenacker 15, 8200 Schaffhausen, Switzerland
O: +41 52 630 70 94
www.risingtide.ch
